{
    "clinical_study": {
        "@rank": "92422", 
        "arm_group": {
            "arm_group_label": "intravitreal ranibizumab", 
            "arm_group_type": "Experimental", 
            "description": "Ranibizumab was injected into vitreous cavity in the study eye once (0.5 mg/0.05 ml) at least 1 week before performing trabeculectomy with mitomycin C."
        }, 
        "brief_summary": {
            "textblock": "To evaluate the effects of intravitreal ranibizumab (IVR) as adjunctive treatment for\n      trabeculectomy with mitomycin C (TMC) in neovascular glaucoma (NVG)."
        }, 
        "brief_title": "Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Glaucoma, Neovascular", 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Neovascular"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective study of 15 consecutive eyes from 14 patients (One patients had NVG in\n      both eyes at presentation.) with NVG presented at the Department of Ophthalmology, Faculty\n      of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand between December 2008\n      and December 2009. Each eye received IVR (0.5 mg/0.05 ml) 1 week before TMC. Trabeculectomy\n      was performed with fornix-based conjunctival flap method."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Consecutive patients with neovascular glaucoma\n\n          -  Age more than 80 year old\n\n          -  Provide written informed consent\n\n        Exclusion Criteria:\n\n          -  Un-cooperated patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01922154", 
            "org_study_id": "NK002"
        }, 
        "intervention": {
            "arm_group_label": "intravitreal ranibizumab", 
            "description": "The patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.", 
            "intervention_name": "intravitreal ranibizumab", 
            "intervention_type": "Drug", 
            "other_name": "Lucentis; Genentech Inc, San Francisco, CA"
        }, 
        "intervention_browse": {
            "mesh_term": "Angiogenesis Inhibitors"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Angiogenesis inhibitors", 
            "Neovascular", 
            "Intraocular pressure", 
            "Retinal Vein Occlusion", 
            "Vascular Endothelial Growth Factor"
        ], 
        "lastchanged_date": "August 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bangkok", 
                    "country": "Thailand", 
                    "zip": "10700"
                }, 
                "name": "Naris Kitnarong"
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "1", 
        "official_title": "Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma", 
        "overall_official": {
            "affiliation": "Mahidol University", 
            "last_name": "Naris Kitnarong, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Thailand: Ethical Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The change of intraocular pressure (IOP)between before trabeculectomy with mitomycin C (TMC) and after TMC. We compared this change at several time points such as at 6, 12 months and at last visit. The most important is the change of IOP between before TMC and at last visit as well as the level of IOP at last visit which is at of the longest follow-up time.", 
            "measure": "The change of intraocular pressure (IOP)", 
            "safety_issue": "No", 
            "time_frame": "Change of IOP between before trabeculectomy and at last visit"
        }, 
        "reference": [
            {
                "PMID": "18425438", 
                "citation": "Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther. 2008 May;25(5):438-43. doi: 10.1007/s12325-008-0047-5."
            }, 
            {
                "PMID": "20179624", 
                "citation": "Alkawas AA, Shahien EA, Hussein AM. Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C. J Glaucoma. 2010 Dec;19(9):622-6. doi: 10.1097/IJG.0b013e3181ccb794."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01922154"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Siriraj Hospital", 
            "investigator_full_name": "Naris Kitnarong", 
            "investigator_title": "Associate professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "18173426", 
            "citation": "Dunavoelgyi R, Zehetmayer M, Simader C, Schmidt-Erfurth U. Rapid improvement of radiation-induced neovascular glaucoma and exudative retinal detachment after a single intravitreal ranibizumab injection. Clin Experiment Ophthalmol. 2007 Dec;35(9):878-80. doi: 10.1111/j.1442-9071.2007.01632.x."
        }, 
        "secondary_outcome": {
            "description": "Blood pressure (mmHg) change", 
            "measure": "The safety of intravitreal ranibizumab (IVR)", 
            "safety_issue": "Yes", 
            "time_frame": "immediately after IVR"
        }, 
        "source": "Siriraj Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Siriraj Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2009", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}